does tirzepatide cause vision problems Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort GLP-1 Medications and Your Eye

Description

Co-formulation of semaglutide with the absorption enhancer sodium N -(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) increases its bioavailability, promoting absorption across the gastric epithelium

Semaglutide is approved for multiple indications, including the treatment of type 2 diabetes (under the brand name Ozempic) and for weight management (under the brand name Wegovy)

At 6 months: Subcutaneous group: mean IGF-1 increase of 22%, body composition improvement (lean mass +2.1 kg, fat mass -1.8 kg), sleep quality improvement in 67% of patients Sublingual group: mean IGF-1 increase of 6%, body composition improvement (lean mass +0.4 kg, fat mass -0.6 kg), sleep quality improvement in 31% of patients The subcutaneous group showed statistically significant improvements across all endpoints

Oral semaglutide may potentially alter the pharmacokinetics of concomitantly administered drugs (victim drugs) via the effect on gastric emptying (as has been shown for other GLP-1RAs [21]) or via the effects of the absorption enhancer SNAC, although recent drugdrug interaction (DDI) studies found that oral semaglutide had no clinically meaningful effect on the exposure of four victim drugs (lisinopril, warfarin, digoxin and metformin) commonly used in patients with T2D [23]